Pfizer Inc.
PFEPfizer beats Q2 2026 estimates, raises 2026 revenue guidance to $60.5–$62.5B as CFO Dave Denton plans Aug. 15 exit
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $63.63B | $59.55B | $100.33B | $81.29B | $41.65B | $41.17B | $53.65B | $52.55B |
| Cost of Revenue | $21.78B | $29.21B | $38.24B | $34.41B | $11.77B | $12.62B | $16.01B | $15.78B |
| Gross Profit | $41.85B | $30.34B | $62.09B | $46.88B | $29.88B | $28.55B | $37.64B | $36.77B |
| Gross Margin | 65.77% | 50.95% | 61.89% | 57.67% | 71.74% | 69.34% | 70.16% | 69.97% |
| Operating Expenses | $25.36B | $25.05B | $24.54B | $26.08B | $20.80B | $21.04B | $22.35B | $22.38B |
| Operating Income | $16.48B | $5.29B | $37.55B | $20.79B | $9.09B | $7.51B | $15.29B | $14.39B |
| Operating Margin | 25.91% | 8.89% | 37.43% | 25.58% | 21.81% | 18.24% | 28.50% | 27.39% |
| Net Income | $8.02B | $2.13B | $31.36B | $22.15B | $9.16B | $16.27B | $11.15B | $21.30B |
| Net Margin | 12.60% | 3.58% | 31.26% | 27.25% | 21.99% | 39.52% | 20.79% | 40.55% |
| EPS (Basic) | $1.42 | $0.38 | $5.59 | $3.95 | $1.65 | $2.92 | $1.90 | $3.57 |
| EBITDA | $18.13B | $9.56B | $41.03B | $30.79B | $13.17B | $18.85B | $19.59B | $19.84B |
| Stock Option Compensation Expense | $877.00M | $525.00M | $872.00M | $1.18B | $756.00M | $718.00M | $949.00M | $840.00M |
| Price To Earnings Ratio | 18.74 | 76.17 | 9.16 | 14.93 | 22.33 | 12.71 | 21.79 | 9.62 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $150.27B | $162.46B | $287.35B | $330.74B | $204.48B | $206.83B | $242.98B | $204.95B |
Company coverage
Latest news
Show 12 more stories
Insider Trading
View AllCompany
About the company
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.